妊娠期接种新冠疫苗的安全性:系统综述与Meta分析
该系统综述与Meta分析检索至2021年9月的文献,纳入71项研究,涉及17,719,495名孕妇和389只妊娠动物,其中9项新冠疫苗研究有7项共309,164名孕妇,多数接种mRNA疫苗;未发现目前使用的新冠疫苗在妊娠期存在安全性问题,非mRNA疫苗仍需可靠安全性数据。
要点
- 调整混杂因素后的Meta分析显示,无论疫苗种类或接种孕周,均未发现与不良结局的关联。
- 不良妊娠结局报告率与反应原性均未超过预期背景发生率,唯一例外为两项研究报告的产后出血(10.40%,95%CI 6.49-15.10%)。
- 动物研究结果与孕妇研究结果一致。
核心结论
- 未发现目前接种的新冠疫苗在妊娠期存在安全性问题,但非mRNA新冠疫苗仍需可靠的安全性数据,补充实验与真实世界证据可提高接种覆盖率。
研究设计与样本
- 系统综述与Meta分析,检索文献数据库自建库至2021年9月,无语言限制,并检索新冠疫苗网站及其他系统综述和纳入研究的参考文献列表(PROSPERO CRD42021234185);共纳入71项研究,涉及17,719,495名孕妇和389只妊娠动物。
主要发现
- 文献检索获得8,837条记录;94%的研究在高收入国家开展,51%为队列研究,15%被评定为高偏倚风险。
- 共识别9项新冠疫苗研究,其中7项涉及309,164名孕妇,多数暴露于mRNA疫苗;非新冠疫苗中最常见的暴露为AS03佐剂和铝佐剂。
- 调整潜在混杂因素的研究Meta分析显示,无论疫苗种类或接种孕周,均未发现与不良结局的关联;不良妊娠结局报告率与反应原性均未超过预期背景发生率,ASO3佐剂或铝佐剂非新冠疫苗在非对照研究/组的比例Meta分析中亦如此。
- 唯一例外为两项研究报告的接种新冠疫苗后产后出血(10.40%;95%CI 6.49-15.10%);其中一项研究与非暴露孕妇比较,差异未达统计学显著(调整OR 1.09;95%CI 0.56-2.12)。
- 动物研究结果与孕妇研究结果一致。
关键数值与推荐
- 产后出血:接种新冠疫苗后10.40%(95%CI 6.49-15.10%),由两项研究报告。
- 产后出血比较:与非暴露孕妇相比,调整OR 1.09(95%CI 0.56-2.12),差异未达统计学显著,仅一项研究提供该比较。
临床怎么用
- 作者认为未发现目前接种的新冠疫苗在妊娠期存在安全性问题;作者指出补充实验与真实世界证据可提高接种覆盖率,非mRNA新冠疫苗仍需可靠安全性数据。
局限性
- 8,837条文献记录中94%的研究在高收入国家开展。
- 15%的研究被归类为高偏倚风险。
- 产后出血仅由两项研究报告,与非暴露孕妇的比较仅一项研究可得。
- 非mRNA新冠疫苗仍需可靠的安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Assessment of COVID-19 vaccines safety during pregnancy is urgently needed. METHODS: We conducted a systematic review and meta-analysis to evaluate the safety of COVID-19 vaccines, including their components and technological platforms used in other vaccines during pregnancy and animal studies to complement direct evidence. We searched literature databases from its inception to September 2021 without language restriction, COVID-19 vaccine websites, and reference lists of other systematic reviews and the included studies. Pairs of reviewers independently selected, data extracted, and assessed the risk of bias of the studies. Discrepancies were resolved by consensus. (PROSPERO CRD42021234185). RESULTS: We retrieved 8,837 records from the literature search; 71 studies were included, involving 17,719,495 pregnant persons and 389 pregnant animals. Most studies (94%) were conducted in high-income countries, were cohort studies (51%), and 15% were classified as high risk of bias. We identified nine COVID-19 vaccine studies, seven involving 309,164 pregnant persons, mostly exposed to mRNA vaccines. Among non-COVID-19 vaccines, the most frequent exposures were AS03 and aluminum-based adjuvants. A meta-analysis of studies that adjusted for potential confounders showed no association with adverse outcomes, regardless of the vaccine or the trimester of vaccination. Neither the reported rates of adverse pregnancy outcomes nor reactogenicity exceeded expected background rates, which was the case for ASO3- or aluminum-adjuvanted non-COVID-19 vaccines in the proportion meta-analyses of uncontrolled studies/arms. The only exception was postpartum hemorrhage after COVID-19 vaccination (10.40%; 95% CI: 6.49-15.10%), reported by two studies; however, the comparison with non-exposed pregnant persons, available for one study, found non-statistically significant differences (adjusted OR 1.09; 95% CI 0.56-2.12). Animal studies showed consistent results with studies in pregnant persons. CONCLUSION: We found no safety concerns for currently administered COVID-19 vaccines during pregnancy. Additional experimental and real-world evidence could enhance vaccination coverage. Robust safety data for non-mRNA-based COVID-19 vaccines are still needed.
引用
- Ciapponi A, Berrueta M, P K Parker E, et al. Safety of COVID-19 vaccines during pregnancy: A systematic review and meta-analysis. Vaccine. 2023. PMID: 37012114. doi:10.1016/j.vaccine.2023.03.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。